Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
felzartamab + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Felzartamab (TJ202, MOR202) is a fully human monoclonal antibody that targets the cell surface glycoprotein CD38, which is highly and uniformly expressed on malignant plasma cells in multiple myeloma. It is derived from MorphoSys' HuCAL antibody technology and developed through a partnership between MorphoSys and I-Mab. Felzartamab binds to CD38 on tumor cells, recruiting immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), but does not involve complement-dependent cytotoxicity (CDC). The combination of felzartamab with lenalidomide (an immunomodulatory agent) and dexamethasone (a corticosteroid) has been investigated in relapsed/refractory multiple myeloma. Lenalidomide modulates the immune system and inhibits angiogenesis, while dexamethasone exerts anti-inflammatory and antitumor effects. This combination aims to enhance antimyeloma activity by targeting different pathways involved in disease progression[1][2][3][4][5][7].
- Other names
- felzartamab
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on felzartamab + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on felzartamab + lenalidomide + dexamethasone.